Rate My Professor Jennifer Elisseeff

Elisseeff's research specializes in regenerative immunology, biomaterials, aging, single cell analysis, and regenerative medicine, with pioneering work on injectable biomaterials for tissue engineering therapies. She has cofounded several biotechnology companies, including Cartilix, Inc. in 2004, which was acquired by Biomet Inc. in 2009, and Aegeria Soft Tissue and Tissue Repair in 2009, focusing on orthopedic disease treatment, soft tissue regeneration, and wound healing. Her scholarly contributions include over 200 articles, book chapters, and patent applications, along with more than 130 national and international invited lectures. Notable publications are "Transdermal Photopolymerization for Minimally Invasive Implantation" (Proceedings of the National Academy of Sciences, USA, 1999), "Photoencapsulation of chondrocytes in poly(ethylene oxide)-based semi-interpenetrating networks" (Journal of Biomedical Materials Research, 2000), and "Controlled-release of IGF-I and TGF-beta1 in a photopolymerizing hydrogel for cartilage tissue engineering" (Journal of Orthopaedic Research, 2001). Elisseeff has earned prestigious honors, including election to the National Academy of Sciences in 2023, the National Academy of Engineering and National Academy of Medicine in 2018—making her the first Johns Hopkins faculty member elected to all three—the American Academy of Arts and Sciences in 2022, the NIH Director’s Pioneer Award in 2019, fellowship in the American Institute for Medical and Biological Engineering in 2008, and the Young Global Leader designation by the World Economic Forum in 2008. She serves on scientific advisory boards for Bausch and Lomb, Kythera Biopharmaceutical, and Cellular Bioengineering Inc., as well as the State of Maryland’s Technology Development Corporation.